Stock APS APTOSE BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Aptose Biosciences Inc.

Equities

APS

CA03835T3091

Delayed Toronto S.E.
Other stock markets
 01:21:39 2024-04-30 pm EDT 		5-day change 1st Jan Change
1.69 CAD +2.42% Intraday chart for Aptose Biosciences Inc. +2.42% -49.55%
Apr. 25 Certain Warrants of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024. CI
Apr. 25 Certain Common Shares of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024. CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aptose Biosciences Up 3% After Hours as its 2023 Loss Widens on Higher R&D Spending
MT
Aptose Biosciences Brief: Says Luxeptinib G3 Formulation Achieved "Desired Levels and Positions for Future Trials"
MT
Aptose Biosciences Brief: Says Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML; Adds Tuspetinib "Continues Broad Activity Across Mutations with Excellent Safety Profile"
MT
Aptose Biosciences Brief: Q4 Basic and diluted loss per Common Share US$7.58
MT
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aptose Biosciences Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
MT
Aptose Biosciences Brief: Said Over Weekend Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
MT
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
CI
Aptose Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Correction: -- Aptose Biosciences Brief: Net Loss per share, Basic and diluted C$(1.76)
MT
Aptose Biosciences Third-Quarter Loss Widens on Higher R&D Spending
MT
Aptose Biosciences Brief: Net Loss per share, Basic and diluted US$(1.76)
MT
Aptose Biosciences Brief: Says Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
MT
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
CI
Aptose Biosciences Brief: Presenting Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
MT
Aptose Biosciences Inc. Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
CI
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
CI
Aptose Biosciences Brief: Says to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
MT
Aptose Biosciences to Present Data on Tuspetinib at Haematology Conference in Portugal
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APS Stock
  4. News Aptose Biosciences Inc.
  5. Highlights